Curing childhood cancer requires global effort. In this new blog series, you’ll meet some of the many national and international partners who are working with us to make it happen. We’ll start with Cancer Therapeutics CRC.
A drug called OBI-3424 has been designated an Orphan Drug by the U.S. Food and Drug Administration (FDA) to treat acute lymphoblastic leukaemia, based predominantly on research carried out by our Leukaemia Biology Program.
This week we’re looking at immunotherapy. Harnessing the power of the immune system against cancer is yielding some amazing results. So what are the promises and challenges of immunotherapy?
Last week we hosted a delegation of eight doctors from two leading Chinese children’s hospitals, opening up exciting possibilities for research and clinical collaborations
How does the future look for young Australians with cancer? According to a recent article by Cancer Institute NSW, it’s looking brighter, and our work’s playing a vital role.
If doctors can reliably tell which children are most likely to get their leukaemia back, they can offer more intensive treatment options to prevent it.
WA children with the most aggressive cancers will benefit from an Australian-first personalised medicine clinical trial.
Blood vessels supply the fuel needed for rapid tumour growth and spread. But what happens when the network is disrupted?
Better targeted therapies for neuroblastoma are desperately needed. They’re now a step closer.
Venetoclax has been approved by the Australian Therapeutics Goods Administration (TGA) to treat an adult leukaemia. Could it one day treat childhood leukaemia?